<DOC>
	<DOC>NCT00369941</DOC>
	<brief_summary>This study will investigate the safety and efficacy of MK-0518 versus efavirenz, in combination with TRUVADA, as a therapy for Human Immunodeficiency Virus (HIV)-infected patients not previously treated.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Participant is a male or female at least 18 years of age Participant is HIV positive Participant is na√Øve to antiretroviral therapy (ART) and has not received any ART Participant has received approved or experimental antiretroviral agents in the past Participant has been treated for a viral infection other than HIV such as hepatitis B virus infection with an agent that is active against HIV including but not limited to adefovir or lamivudine (= 7 days total) Participant has documented resistance to tenofovir, emtricitabine, and/or efavirenz Participant has used another experimental HIVintegrase inhibitor Participant has a current (active) diagnosis of acute hepatitis due to any cause Participants with chronic hepatitis including chronic hepatitis B and/or C may enter the study as long as they have stable liver function tests</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>